Showing posts with label Quad Pill. Show all posts
Showing posts with label Quad Pill. Show all posts

Monday, July 2, 2012

Four-in-one Aids drug gets green light


Paris - An experimental once-daily pill that combines four drugs to fight HIV is as safe and effective as commonly-prescribed treatments against the Aids virus, researchers reported in The Lancet on Friday.
Doctors tested the new drug, called Quad, for the third and final phase in which new pharmaceutical products are vetted for safety and effectiveness.
Publication in the British journal follows a recommendation in May by a US Food and Drug Administration (FDA) advisory panel to approve Quad for previously untreated adults infected with HIV-1. A final decision is expected by August.
The first trial entailed testing Quad against a three-in-one pill, Atripla, which since 2006 has been a standard treatment for the human immunodeficiency virus (HIV).

Saturday, January 1, 2011

Gilead could change the game for HIV patients

Date: Friday, December 31, 2010, 3:00am PST

Biotech: Pill to watch-Gilead Sciences' Quad pill
 Foster City-based Gilead could change the game for HIV patients and its bottom line, adding a new drug and booster to its once-a-day pill.
The so-called Quad pill and its elements are undergoing three Phase III studies. A fourth 700-patient trial is enrolling.
About half of the HIV patients who start therapy in the United States already use Gilead’s three-in-one Atripla, which uses Bristol-Myers Squibb’s Sustiva. The Quad pill drops the Bristol-Myers Squibb drug and uses Viread, Emtriva and a new Gilead drug called elvitegravir plus an elvitegravir booster.
Wall Street analysts have pegged the pill as a $4 billion-a-year ...


Read more: Biotech: Pill to watch-Gilead Sciences' Quad pill | San Francisco Business Times